id	sid	eid	entity	type
bptjm-64	1	1	berkeley pharma tech journal	ORG
bptjm-64	1	2	august 11	DATE
bptjm-64	1	3	2023	CARDINAL
bptjm-64	1	4	23	CARDINAL
bptjm-64	1	5	2024	DATE
bptjm-64	1	6	2024	DATE
bptjm-64	1	7	4.0	CARDINAL
bptjm-64	3	1	the past several years	DATE
bptjm-64	4	1	cd8+	LOC
bptjm-64	5	1	pd-1/pdl1	EVENT
bptjm-64	9	1	sanchitha kannabran	PERSON
bptjm-64	9	2	akshaya ajan	PERSON
bptjm-64	9	3	leanne lui	PERSON
bptjm-64	9	4	zaden	GPE
bptjm-64	9	5	1	CARDINAL
bptjm-64	10	1	ecm	ORG
bptjm-64	12	1	1900s.3	CARDINAL
bptjm-64	16	1	two	CARDINAL
bptjm-64	16	2	anti-pd-1	NORP
bptjm-64	16	3	ifn-ɣ	ORG
bptjm-64	18	1	berkeley pharma tech journal	ORG
bptjm-64	18	2	114	CARDINAL
bptjm-64	19	1	2	CARDINAL
bptjm-64	19	2	ecm	ORG
bptjm-64	20	1	m1 and m2	PRODUCT
bptjm-64	24	1	growth.10	DATE
bptjm-64	25	1	berkeley pharma tech journal	ORG
bptjm-64	25	2	115	CARDINAL
bptjm-64	25	3	1	CARDINAL
bptjm-64	26	1	m1 and m2	PRODUCT
bptjm-64	26	2	tregs	ORG
bptjm-64	32	1	berkeley pharma tech journal	ORG
bptjm-64	32	2	116	CARDINAL
bptjm-64	32	3	ecm	ORG
bptjm-64	34	1	chen et al	PERSON
bptjm-64	35	1	ecm	ORG
bptjm-64	35	2	populations.12	PERSON
bptjm-64	36	1	therapy.12	GPE
bptjm-64	37	1	3	CARDINAL
bptjm-64	39	1	berkeley pharma tech journal	ORG
bptjm-64	39	2	117	CARDINAL
bptjm-64	44	1	2	CARDINAL
bptjm-64	44	2	a. vascular	PERSON
bptjm-64	47	1	berkeley pharma tech journal	ORG
bptjm-64	47	2	118	CARDINAL
bptjm-64	47	3	ctls	GPE
bptjm-64	48	1	fda	ORG
bptjm-64	48	2	1	CARDINAL
bptjm-64	48	3	4	CARDINAL
bptjm-64	49	1	lag3	ORG
bptjm-64	49	2	cd39	PRODUCT
bptjm-64	49	3	cd73	PRODUCT
bptjm-64	49	4	cd47	ORG
bptjm-64	49	5	3.1	CARDINAL
bptjm-64	49	6	ctls	GPE
bptjm-64	50	1	fda	ORG
bptjm-64	50	2	1	CARDINAL
bptjm-64	50	3	4	CARDINAL
bptjm-64	50	4	lag3	ORG
bptjm-64	50	5	cd39	PRODUCT
bptjm-64	50	6	cd73	PRODUCT
bptjm-64	50	7	cd47	ORG
bptjm-64	52	1	pd-l1	GPE
bptjm-64	52	2	berkeley pharma tech journal	ORG
bptjm-64	53	1	119	CARDINAL
bptjm-64	53	2	therapy.16	CARDINAL
bptjm-64	54	1	anti-pd-l1	NORP
bptjm-64	55	1	qian et al	PERSON
bptjm-64	56	1	anti-pd	NORP
bptjm-64	56	2	120	CARDINAL
bptjm-64	56	3	anti-pd	NORP
bptjm-64	58	1	anti-pd therapy.15	NORP
bptjm-64	59	1	3.2	CARDINAL
bptjm-64	59	2	ctls	GPE
bptjm-64	59	3	berkeley pharma tech journal	ORG
bptjm-64	59	4	120	CARDINAL
bptjm-64	60	1	cd28	ORG
bptjm-64	61	1	costimulation signals.14	ORG
bptjm-64	61	2	fda	ORG
bptjm-64	63	1	3.3	CARDINAL
bptjm-64	63	2	3	CARDINAL
bptjm-64	63	3	nk	ORG
bptjm-64	64	1	nk	ORG
bptjm-64	64	2	cll	ORG
bptjm-64	65	1	berkeley pharma tech journal	ORG
bptjm-64	65	2	121	CARDINAL
bptjm-64	65	3	cll	ORG
bptjm-64	66	1	cll	ORG
bptjm-64	67	1	the xbp1 gene.21	ORG
bptjm-64	67	2	2022	CARDINAL
bptjm-64	67	3	zundell et al.	PERSON
bptjm-64	67	4	over 50%	PERCENT
bptjm-64	69	1	xbp1	ORG
bptjm-64	69	2	xbp1	ORG
bptjm-64	71	1	berkeley pharma tech journal	ORG
bptjm-64	71	2	122	CARDINAL
bptjm-64	71	3	response.21	PRODUCT
bptjm-64	72	1	ma et al	PERSON
bptjm-64	72	2	xbp1	ORG
bptjm-64	72	3	exhaustion.22	ORG
bptjm-64	72	4	3.5	CARDINAL
bptjm-64	73	1	angiogenesis.19 berkeley pharma tech journal	ORG
bptjm-64	73	2	123	CARDINAL
bptjm-64	74	1	daniel chiu et al	PERSON
bptjm-64	74	2	antiangiogenic	NORP
bptjm-64	76	1	vegf and pd-1 expression.16 4	LAW
bptjm-64	77	1	cd8+ t	ORG
bptjm-64	78	1	feng y. et al.	PERSON
bptjm-64	79	1	berkeley pharma tech journal	ORG
bptjm-64	79	2	124	CARDINAL
bptjm-64	83	1	4.1	CARDINAL
bptjm-64	86	1	2020	DATE
bptjm-64	89	1	vista	ORG
bptjm-64	90	1	berkeley pharma tech journal	ORG
bptjm-64	90	2	125	CARDINAL
bptjm-64	90	3	vista	ORG
bptjm-64	90	4	vista	ORG
bptjm-64	91	1	levels5	PRODUCT
bptjm-64	96	1	4.2	CARDINAL
bptjm-64	102	1	gls	ORG
bptjm-64	102	2	gls	ORG
bptjm-64	103	1	gls	ORG
bptjm-64	104	1	gls	ORG
bptjm-64	104	2	pharma tech journal	ORG
bptjm-64	104	3	126	CARDINAL
bptjm-64	112	1	tregs	ORG
bptjm-64	112	2	dcs	ORG
bptjm-64	112	3	2,3	CARDINAL
bptjm-64	112	4	ido	ORG
bptjm-64	112	5	ido	ORG
bptjm-64	113	1	berkeley pharma tech journal	ORG
bptjm-64	113	2	127	CARDINAL
bptjm-64	113	3	cd8+ t	ORG
bptjm-64	114	1	icbs	GPE
bptjm-64	115	1	llc xenograft mouse models	FAC
bptjm-64	116	1	ctls	GPE
bptjm-64	116	2	cpt1a	GPE
bptjm-64	118	1	1	CARDINAL
bptjm-64	118	2	tfr1	ORG
bptjm-64	118	3	tfr1	ORG
bptjm-64	118	4	supply.30	LOC
bptjm-64	119	1	berkeley pharma tech journal	ORG
bptjm-64	119	2	128	CARDINAL
bptjm-64	119	3	3	CARDINAL
bptjm-64	120	1	ido	ORG
bptjm-64	121	1	ido	ORG
bptjm-64	121	2	dcs	ORG
bptjm-64	122	1	4.3	CARDINAL
bptjm-64	124	1	one	CARDINAL
bptjm-64	126	1	berkeley pharma tech journal	ORG
bptjm-64	126	2	129	CARDINAL
bptjm-64	130	1	two	CARDINAL
bptjm-64	130	2	pd-1/pd-l1	ORG
bptjm-64	131	1	the pd-1/pd-l1	EVENT
bptjm-64	135	1	berkeley pharma tech journal	ORG
bptjm-64	135	2	130	CARDINAL
bptjm-64	138	1	5	CARDINAL
bptjm-64	139	1	ctl	ORG
bptjm-64	141	1	angiogenesis.33	PERSON
bptjm-64	141	2	zhao et al	PERSON
bptjm-64	142	1	atezolizumab	PERSON
bptjm-64	143	1	bevacizumab	PERSON
bptjm-64	145	1	zhao et al	PERSON
bptjm-64	146	1	atezolizumab	PERSON
bptjm-64	147	1	berkeley pharma tech journal	ORG
bptjm-64	147	2	131	CARDINAL
bptjm-64	149	1	5.1	CARDINAL
bptjm-64	149	2	pembrolizumab	PERSON
bptjm-64	150	1	pembrolizumab	PERSON
bptjm-64	150	2	regression.14	ORG
bptjm-64	151	1	2022	CARDINAL
bptjm-64	152	1	pembrolizumab	PERSON
bptjm-64	152	2	pemetrexed.34	ORG
bptjm-64	152	3	136	CARDINAL
bptjm-64	152	4	pembrolizumab	PERSON
bptjm-64	152	5	berkeley pharma tech journal	ORG
bptjm-64	152	6	132 survival	QUANTITY
bptjm-64	152	7	september 2022	DATE
bptjm-64	154	1	41	CARDINAL
bptjm-64	154	2	three	CARDINAL
bptjm-64	155	1	nkg7	NORP
bptjm-64	156	1	5.2	CARDINAL
bptjm-64	157	1	approximately 40%	PERCENT
bptjm-64	157	2	melanoma.36	ORG
bptjm-64	157	3	pembrolizumab	PERSON
bptjm-64	157	4	16	CARDINAL
bptjm-64	159	1	outcomes.36 berkeley pharma tech journal	ORG
bptjm-64	160	1	133	CARDINAL
bptjm-64	161	1	29	CARDINAL
bptjm-64	161	2	four	CARDINAL
bptjm-64	162	1	82%	PERCENT
bptjm-64	162	2	only 10%	PERCENT
bptjm-64	162	3	5.3	CARDINAL
bptjm-64	162	4	fourth	ORDINAL
bptjm-64	163	1	one-year	DATE
bptjm-64	165	1	three	CARDINAL
bptjm-64	165	2	berkeley pharma tech journal	ORG
bptjm-64	165	3	134	CARDINAL
bptjm-64	165	4	fourth	ORDINAL
bptjm-64	165	5	ccrt	NORP
bptjm-64	166	1	huang et al.	PERSON
bptjm-64	167	1	august 2022	DATE
bptjm-64	167	2	27	CARDINAL
bptjm-64	167	3	20	CARDINAL
bptjm-64	168	1	12	CARDINAL
bptjm-64	168	2	75%	PERCENT
bptjm-64	168	3	9 to 22 months	DATE
bptjm-64	169	1	only one	CARDINAL
bptjm-64	170	1	ccrt	GPE
bptjm-64	170	2	ccrt	GPE
bptjm-64	171	1	ccrt	GPE
bptjm-64	172	1	ctls	GPE
bptjm-64	172	2	cll	ORG
bptjm-64	173	1	cll	GPE
bptjm-64	174	1	relatlimab	PERSON
bptjm-64	175	1	nk	ORG
bptjm-64	176	1	20	CARDINAL
bptjm-64	176	2	berkeley pharma tech journal	ORG
bptjm-64	176	3	135	CARDINAL
bptjm-64	177	1	cll	ORG
bptjm-64	178	1	cll	ORG
bptjm-64	179	1	20	CARDINAL
bptjm-64	181	1	41	CARDINAL
bptjm-64	182	1	41	CARDINAL
bptjm-64	183	1	6	CARDINAL
bptjm-64	184	1	one	CARDINAL
bptjm-64	185	1	berkeley pharma tech journal	ORG
bptjm-64	185	2	136	CARDINAL
bptjm-64	185	3	ribas et al.	PERSON
bptjm-64	186	1	presence.48 pembrolizumab	GPE
bptjm-64	187	1	virus.48	LOC
bptjm-64	187	2	vegf/vegf-a	ORG
bptjm-64	188	1	cd8+	LOC
bptjm-64	189	1	tls	ORG
bptjm-64	193	1	two	CARDINAL
bptjm-64	194	1	berkeley pharma tech journal	ORG
bptjm-64	194	2	137	CARDINAL
bptjm-64	196	1	63	CARDINAL
bptjm-64	196	2	november 2023.50	DATE
bptjm-64	196	3	second	ORDINAL
bptjm-64	196	4	anti-pd-l1/vegf	NORP
bptjm-64	198	1	374	CARDINAL
bptjm-64	198	2	december 2025.51 7	DATE
bptjm-64	202	1	berkeley pharma tech journal	ORG
bptjm-64	202	2	138	CARDINAL
bptjm-64	202	3	1	CARDINAL
bptjm-64	202	4	jung jg	PERSON
bptjm-64	202	5	le a.	PERSON
bptjm-64	203	1	springerlink	PERSON
bptjm-64	204	1	january 1, 1970	DATE
bptjm-64	205	1	8-3-030-65768-0_15	TIME
bptjm-64	206	1	2	CARDINAL
bptjm-64	206	2	rad h	GPE
bptjm-64	209	1	2020;41(3):1474	CARDINAL
bptjm-64	210	1	3	CARDINAL
bptjm-64	210	2	dobosz p	PERSON
bptjm-64	210	3	dzieciątkowski t.	PERSON
bptjm-64	212	1	december 3, 2019	DATE
bptjm-64	214	1	4	CARDINAL
bptjm-64	214	2	yaqi li	PERSON
bptjm-64	214	3	jing liu	PERSON
bptjm-64	214	4	long gao	PERSON
bptjm-64	214	5	yuan liu	PERSON
bptjm-64	214	6	fang meng	PERSON
bptjm-64	214	7	xiaoan li	PERSON
bptjm-64	214	8	f. xiao-feng qin	PERSON
bptjm-64	214	9	220	CARDINAL
bptjm-64	214	10	2020	DATE
bptjm-64	214	11	88-96	DATE
bptjm-64	214	12	0165-2478	DATE
bptjm-64	215	1	5	CARDINAL
bptjm-64	215	2	bader je	PERSON
bptjm-64	215	3	voss k	PERSON
bptjm-64	217	1	2020;78(6):1019-1033	CARDINAL
bptjm-64	219	1	6	CARDINAL
bptjm-64	219	2	orban	ORG
bptjm-64	221	1	nat	ORG
bptjm-64	222	1	2022;3(12):1464	CARDINAL
bptjm-64	222	2	1483	CARDINAL
bptjm-64	223	1	doi:10.1038	ORG
bptjm-64	223	2	022-00470	CARDINAL
bptjm-64	224	1	wang jx	PERSON
bptjm-64	224	2	choi syc	GPE
bptjm-64	224	3	niu	ORG
bptjm-64	225	1	j mol sci	PERSON
bptjm-64	228	1	anderson	PERSON
bptjm-64	228	2	simon mc	PERSON
bptjm-64	230	1	cb	ORG
bptjm-64	230	2	https://pubmed.ncbi.nlm.nih.gov/32810447/. 9	DATE
bptjm-64	230	3	bindea g	PERSON
bptjm-64	230	4	hahn wc	PERSON
bptjm-64	230	5	rooney ms	PERSON
bptjm-64	232	1	august 18	DATE
bptjm-64	232	2	2022	CARDINAL
bptjm-64	234	1	10	CARDINAL
bptjm-64	235	1	kazama k	PERSON
bptjm-64	235	2	satoyoshi	ORG
bptjm-64	237	1	march 1, 2020	DATE
bptjm-64	240	1	hien tt	PERSON
bptjm-64	240	2	kawasaki j	PERSON
bptjm-64	242	1	june 4, 2003	DATE
bptjm-64	243	1	12	CARDINAL
bptjm-64	244	1	felix peix	PERSON
bptjm-64	244	2	oriol casanovas	ORG
bptjm-64	244	3	86	CARDINAL
bptjm-64	244	4	3	CARDINAL
bptjm-64	244	5	2022	CARDINAL
bptjm-64	244	6	199	CARDINAL
bptjm-64	244	7	issn 1044-579x	PERSON
bptjm-64	244	8	13	CARDINAL
bptjm-64	245	1	li y, liu j	PERSON
bptjm-64	245	2	gao l	PERSON
bptjm-64	247	1	2020;220:88	CARDINAL
bptjm-64	247	2	doi:10.1016/j.imlet.2019.03.006	ORG
bptjm-64	247	3	berkeley pharma tech journal	ORG
bptjm-64	247	4	139 14	DATE
bptjm-64	250	1	annu rev	ORG
bptjm-64	251	1	2021;16:223-249	CARDINAL
bptjm-64	253	1	vesely md	PERSON
bptjm-64	253	2	zhang t	PERSON
bptjm-64	253	3	chen l. resistance mechanisms	PERSON
bptjm-64	254	1	annual	DATE
bptjm-64	255	1	2022;40(1):45-74	DATE
bptjm-64	257	1	feng y	PERSON
bptjm-64	257	2	wu j	PERSON
bptjm-64	257	3	chen j	PERSON
bptjm-64	258	1	today	DATE
bptjm-64	259	1	2021;38:101194	CARDINAL
bptjm-64	260	1	qian j	PERSON
bptjm-64	260	2	wang c	PERSON
bptjm-64	260	3	wang	PERSON
bptjm-64	263	1	2018;15:290	ORDINAL
bptjm-64	264	1	coutzac c	ORG
bptjm-64	264	2	ben abdelghani m	PERSON
bptjm-64	267	1	2022;54(10):1335-1341	CARDINAL
bptjm-64	268	1	19	CARDINAL
bptjm-64	269	1	zhao y, guo s	PERSON
bptjm-64	269	2	deng j	PERSON
bptjm-64	271	1	2022;18(9):3845-3858	DATE
bptjm-64	272	1	20	CARDINAL
bptjm-64	273	1	sordo-bahamonde	PERSON
bptjm-64	273	2	gonzález-rodríguez ap	PERSON
bptjm-64	273	3	lag-3	GPE
bptjm-64	273	4	relatlimab	PERSON
bptjm-64	273	5	bms-986016	DATE
bptjm-64	274	1	pubmed central	ORG
bptjm-64	276	1	zundell ja	PERSON
bptjm-64	276	2	lin j	PERSON
bptjm-64	277	1	pubmed central	ORG
bptjm-64	277	2	pmc	ORG
bptjm-64	278	1	doi:10.1158/0008-5472.can-21-1545 22	PERSON
bptjm-64	279	1	ma x	PERSON
bptjm-64	281	1	2019;30(1	CARDINAL
bptjm-64	282	1	doi:10.1016	GPE
bptjm-64	282	2	23	CARDINAL
bptjm-64	283	1	chiu	PERSON
bptjm-64	284	1	pd-l1	GPE
bptjm-64	286	1	2023;3(1):130-139	CARDINAL
bptjm-64	287	1	2023 jan 25	DATE
bptjm-64	288	1	9764.crc-22-0420 24	TIME
bptjm-64	288	2	sanmamed mf	ORG
bptjm-64	288	3	nie x	PERSON
bptjm-64	288	4	desai ss	PERSON
bptjm-64	291	1	2021;11(7):1700-1715	CARDINAL
bptjm-64	292	1	doi:10.1158/2159	PERSON
bptjm-64	293	1	khodaei t	PERSON
bptjm-64	293	2	suresh ap	PERSON
bptjm-64	293	3	acharya ap	PERSON
bptjm-64	294	1	adv drug deliv	ORG
bptjm-64	295	1	2022;184(114242):114242. doi:10.1016	QUANTITY
bptjm-64	295	2	26	CARDINAL
bptjm-64	296	1	bian x	PERSON
bptjm-64	296	2	liu r	PERSON
bptjm-64	296	3	meng y	PERSON
bptjm-64	298	1	lu z. lipid	PERSON
bptjm-64	301	1	27	CARDINAL
bptjm-64	302	1	liu x	PERSON
bptjm-64	302	2	hartman cl	PERSON
bptjm-64	302	3	li l	PERSON
bptjm-64	303	1	sci transl med .	ORG
bptjm-64	304	1	berkeley pharma tech journal	ORG
bptjm-64	304	2	140	CARDINAL
bptjm-64	305	1	28	CARDINAL
bptjm-64	306	1	luo y	PERSON
bptjm-64	306	2	wang h	PERSON
bptjm-64	306	3	liu b	PERSON
bptjm-64	306	4	wei j. fatty	PERSON
bptjm-64	307	1	curr	PERSON
bptjm-64	308	1	2022;24(5):659-670	CARDINAL
bptjm-64	310	1	wu l	PERSON
bptjm-64	310	2	zhang x	PERSON
bptjm-64	310	3	zheng l	PERSON
bptjm-64	310	4	zhao h	PERSON
bptjm-64	310	5	yan g	PERSON
bptjm-64	310	6	zhou y, lei j	PERSON
bptjm-64	310	7	zhang j	PERSON
bptjm-64	310	8	wang j	PERSON
bptjm-64	310	9	xin r	PERSON
bptjm-64	310	10	jiang l	PERSON
bptjm-64	310	11	peng j	PERSON
bptjm-64	310	12	chen	PERSON
bptjm-64	310	13	lam sm	PERSON
bptjm-64	310	14	shui g	PERSON
bptjm-64	310	15	li y. ripk3	PERSON
bptjm-64	311	1	2020	DATE
bptjm-64	311	2	1;8(5):710-721	CARDINAL
bptjm-64	312	1	10.1158/2326-6066.cir-19-0261	CARDINAL
bptjm-64	313	1	30	CARDINAL
bptjm-64	313	2	vela d. iron	PERSON
bptjm-64	315	1	june 24	DATE
bptjm-64	315	2	2020:39	CARDINAL
bptjm-64	317	1	pitt jm	PERSON
bptjm-64	317	2	soria jc	PERSON
bptjm-64	317	3	kroemer g	PERSON
bptjm-64	317	4	zitvogel l.	PERSON
bptjm-64	318	1	ann oncol	PERSON
bptjm-64	319	1	2016;27(8):1482-1492	CARDINAL
bptjm-64	320	1	doi:10.1093/annonc/mdw168	ORG
bptjm-64	320	2	32	CARDINAL
bptjm-64	321	1	datta m	PERSON
bptjm-64	321	2	nishikawa h	ORG
bptjm-64	321	3	hodi fs	PERSON
bptjm-64	321	4	jain rk	PERSON
bptjm-64	322	1	pubmed central	ORG
bptjm-64	323	1	33	CARDINAL
bptjm-64	324	1	graves ee	PERSON
bptjm-64	326	1	pubmed central	ORG
bptjm-64	327	1	doi:10.1016	GPE
bptjm-64	327	2	34	CARDINAL
bptjm-64	328	1	reckamp kl	PERSON
bptjm-64	328	2	dragnev kh	PERSON
bptjm-64	328	3	pembrolizumab	PERSON
bptjm-64	329	1	j clin oncol	PERSON
bptjm-64	330	1	2022	CARDINAL
bptjm-64	331	1	j clin oncol	PERSON
bptjm-64	332	1	2022;40(21):2295-2306	DATE
bptjm-64	333	1	35	CARDINAL
bptjm-64	334	1	casarrubios m	PERSON
bptjm-64	334	2	provencio m	ORG
bptjm-64	335	1	pubmed central	ORG
bptjm-64	336	1	doi:10.1136/jitc-2022-005320 36	ORG
bptjm-64	337	1	dzutsev ak	ORG
bptjm-64	337	2	mcculloch ja	PERSON
bptjm-64	338	1	pubmed central	ORG
bptjm-64	339	1	37	CARDINAL
bptjm-64	340	1	svekolkin v	PERSON
bptjm-64	340	2	kozlov	PERSON
bptjm-64	340	3	gancharova o	PERSON
bptjm-64	340	4	almog n	ORG
bptjm-64	340	5	fowler n.	PERSON
bptjm-64	342	1	2021;39(6):845-865.e7	ORG
bptjm-64	343	1	doi:10.1016/j.ccell.2021.04.014	ORG
bptjm-64	344	1	38	CARDINAL
bptjm-64	345	1	padrón lj	PERSON
bptjm-64	345	2	maurer dm	ORG
bptjm-64	345	3	o’hara mh	PERSON
bptjm-64	345	4	sotigalimab	PERSON
bptjm-64	345	5	2	CARDINAL
bptjm-64	346	1	pubmed central	ORG
bptjm-64	347	1	doi:10.1038	ORG
bptjm-64	348	1	huang h	PERSON
bptjm-64	348	2	nie c ping	ORG
bptjm-64	348	3	liu x feng	PERSON
bptjm-64	349	1	pubmed central	ORG
bptjm-64	349	2	pmc	ORG
bptjm-64	350	1	berkeley pharma tech journal	ORG
bptjm-64	350	2	141	CARDINAL
bptjm-64	350	3	40	CARDINAL
bptjm-64	351	1	li r	PERSON
bptjm-64	351	2	liu y, yin r	PERSON
bptjm-64	355	1	41	CARDINAL
bptjm-64	356	1	yu j	PERSON
bptjm-64	356	2	md	GPE
bptjm-64	356	3	li s	PERSON
bptjm-64	358	1	pubmed central	ORG
bptjm-64	359	1	doi:10.1038	ORG
bptjm-64	359	2	42	CARDINAL
bptjm-64	362	1	pubmed central	ORG
bptjm-64	363	1	doi:10.1016	GPE
bptjm-64	363	2	43	CARDINAL
bptjm-64	364	1	dunn j	PERSON
bptjm-64	364	2	mccuaig rd	PERSON
bptjm-64	365	1	pubmed central	ORG
bptjm-64	367	1	hruban	ORG
bptjm-64	368	1	pubmed central	ORG
bptjm-64	368	2	pmc	ORG
bptjm-64	369	1	doi:10.1146/annurev.pathmechdis.3.121806.1 54305 45	ORG
bptjm-64	370	1	piersma	PERSON
bptjm-64	371	1	pubmed central	ORG
bptjm-64	373	1	zenz t. genetics	PERSON
bptjm-64	374	1	pubmed central	ORG
bptjm-64	374	2	pmc	ORG
bptjm-64	376	1	hong m	GPE
bptjm-64	376	2	clubb jd	PERSON
bptjm-64	376	3	chen yy	PERSON
bptjm-64	379	1	2020;38(4):473-488	CARDINAL
bptjm-64	380	1	doi:10.1016	GPE
bptjm-64	380	2	48	CARDINAL
bptjm-64	381	1	ribas	PERSON
bptjm-64	384	1	doi:10.1016	PERSON
bptjm-64	385	1	49	CARDINAL
bptjm-64	388	1	nat	ORG
bptjm-64	389	1	2021;2(8):794-802	CARDINAL
bptjm-64	389	2	doi:10.1038	ORG
bptjm-64	389	3	021-00232	CARDINAL
bptjm-64	390	1	sidney kimmel	PERSON
bptjm-64	390	2	johns hopkins	ORG
bptjm-64	390	3	anti-cd137	NORP
bptjm-64	390	4	10/16/18	CARDINAL
bptjm-64	392	1	october 6	DATE
bptjm-64	392	2	2023	CARDINAL
bptjm-64	393	1	51	CARDINAL
bptjm-64	394	1	biotheus inc.	ORG
bptjm-64	396	1	nct05756972	CARDINAL
bptjm-64	397	1	july 13	DATE
bptjm-64	397	2	2023	CARDINAL
bptjm-64	398	1	july 28	DATE
bptjm-64	398	2	2023	CARDINAL
bptjm-64	399	1	https://clinicaltrials.gov/study/nct05756972 berkeley	LOC
bptjm-64	399	2	pharma tech journal	ORG
bptjm-64	399	3	142 kannabran	QUANTITY
bptjm-64	400	1	numbers.pdf kannabran	PERSON
bptjm-64	401	1	64	CARDINAL
bptjm-64	401	2	kannabran	PERSON
bptjm-64	402	1	1) kannabran	QUANTITY